Evidence map›Paper›PMID 39802788›Full record

ArticlemedRxiv : the preprint server for health sciences2025

High versus low dose of 14 days treatment of primaquine in

Virak Eng, Dysoley Lek, Sitha Sin, Lionel Brice Feufack-Donfack, Agnes Orban, Jeremy Salvador, Dynang Seng, Sokleap Heng, Nimol Khim, Kieran Tebben and 7 more

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Virak EngMalaria Research Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.
Dysoley LekNational Center for Parasitology, Entomology and Malaria Control, Phnom Penh, Cambodia.
Sitha SinMalaria Research Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.
Lionel Brice Feufack-DonfackMalaria Research Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.
Agnes OrbanMalaria Research Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.
Jeremy SalvadorMalaria Research Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.
Dynang SengMalaria Research Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.
Sokleap HengMalaria Research Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.
Nimol KhimMalaria Research Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.
Kieran TebbenDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, USA.
Claude FlamandEpidemiology and Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.
Cecile SommenEpidemiology and Public Health Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.
Rob W van der PluijmInfectious Disease Epidemiology and Analytics G5 Unit, Institut Pasteur, Université Paris Cité, Paris, France.
Michael WhiteInfectious Disease Epidemiology and Analytics G5 Unit, Institut Pasteur, Université Paris Cité, Paris, France.
Benoit WitkowskiMalaria Research Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.
David SerreDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, USA.
Jean PopoviciMalaria Research Unit, Institut Pasteur du Cambodge, Phnom Penh, Cambodia.

Funding

Rigorous Assessment of P. vivax Relapses and Primaquine Efficacy for Radical CureR01AI146590 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI SERRE, DAVID · 2020 to 2024
$3.0M
Extent, dynamics and mechanisms of Plasmodium vivax immune evasion caused by PvDBP gene amplificationR01AI173171 · NIAID · INSTITUT PASTEUR DU CAMBODGE · PI Eugenia Lo, Jean POPOVICI · 2023 to 2026
$2.4M
Comprehensive characterization of the genetic factors and the host immune response associated to protection from clinical Plasmodium vivax malariaR01AI175134 · NIAID · INSTITUT PASTEUR DU CAMBODGE · PI TINEKE CANTAERT, Jean POPOVICI · 2023 to 2026
$2.3M
Leveraging access to parasite natural diversity to identify Plasmodium vivax culture-adaptable strain.R61AI187100 · NIAID · INSTITUT PASTEUR DU CAMBODGE · PI Jean POPOVICI · 2025 to 2026
$533k
NIAID NIH HHS R01 AI146590NIAID NIH HHS R01 AI173171NIAID NIH HHS R01 AI175134NIAID NIH HHS R61 AI187100
6 · The paper itself

Abstract

Background: The WHO malaria treatment guidelines recommend a total dose in the range of 3·5 to 7·0 mg/kg of primaquine to eliminate Methods: We conducted an open-label randomised controlled trial in Kampong Speu province, Western Cambodia. Findings: Between Nov 10, 2021, and Feb 10, 2024, a total of 160 patients were enrolled and 156 were allocated to one of the three study arms. Of these, 37 G6PD deficient patients were assigned to the no primaquine arm and 119 G6PD normal patients were randomised: 24 in the no primaquine arm, 49 in the primaquine 3·5 mg/kg arm, and 46 in the primaquine 7·0 mg/kg arm. The proportion of participants with at least one Interpretation: Not providing primaquine to patients led to a considerable rate of Funding: National Institutes of Health (R01AI146590).

Identifiers

PMID39802788
PMCPMC11722477

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.